Abstract:
본 발명은 율피 추출물을 유효 성분으로 함유하는 모발용 화장료 조성물에 관한 것이다. 본 발명에 따른 모발용 화장료 조성물은 율피 추출물을 통해 민감성, 자극성 및/또는 반응성 두피를 안정화시키고, 두피의 가려움, 열감 및/또는 염증을 효과적으로 개선시켜, 두피를 건강하게 유지할 수 있다. 율피, 모발용 화장료 조성물
Abstract:
PURPOSE: An external use skin composition containing chestnut inner bark extract and lavender water is provided to suppress proteinase-activated receptor-2 activation. CONSTITUTION: An external use skin composition for treating atopic dermatitis contains 0.001-50 weight% of chestnut inner bark extract and 0.001-50 weight% of lavender water. The chestnut inner bark extract is obtained by agitation of dried chestnut inner bark in the water at room temperature, filtering, and concentrating the extract. The lavender water is obtained by repeating steps of steaming hot steam vapor to the lavender flower and concentrating. The composition further contains 0.01-15 weight% of ingredient selected from the group consisting of xylitol, anhydrous xylitol, xylitylglucosdie, dextri, rye extract, and Hamamelis extract.
Abstract:
PURPOSE: A compound is provided to treat heart diseases, pain, and hair growth-associated diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating pharmacological stimulation and/or abnormal expression of vaniloid receptor 1(VR1) contains a compound of chemical formula I, II, III, or IV, isomer thereof, or pharmaceutically acceptable salt and pharmaceutically acceptable carrier. The pharmaceutical composition is applied to rat, mouse, livestock, and human. The pharmaceutical composition is used by rectal, intravenous, intramuscular, or subcutaneous administration.
Abstract:
PURPOSE: A cosmetic composition containing Chestnut Inner Bark extract for hair care is provided to stabilize sensitive, irritative, and/or reactive scalp. CONSTITUTION: A cosmetic composition for hair care contains Chestnut Inner Bark extract as an active ingredient. The composition further contains green tea extract, pine needle extract, or ginkgo leaf extract as active ingredient. The active ingredient is contained in 0.01-10.0 weight% based on total weight. The composition is manufactured in the form of hair tonic, hair essence, hair serum, hair treatment, hair conditioner, hair shampoo, or hair lotion.
Abstract:
Provided is 2,4,5-trisubstituted-1,3-thiazole derivatives having excellent inhibiting activity about SPC(sphingosylphosphorylcholine) receptor to treat inflammatory diseases caused by activity of the SPC acceptor. A therapeutic agent for treating inflammatory diseases caused by activity of SPC acceptor comprises a 2,4,5-trisubstituted-1,3-thiazole derivative represented by the formula 1 and pharmaceutically allowable salts thereof. A method for preparing the 2,4,5-trisubstituted-1,3-thiazole derivative consists of the following steps of: reacting methyl cyanocarbonimidodithionate represented by the formula 2 to 2-haloacetophenone in order to synthesize 4-amino-1,3-thiazol represented by the formula 3; and polymerizing chloridation carboxylic acid to 4-amino group of the 4-amino-1,3-thiazol to synthesize 4-N-acyl-1,3-thiazole represented by the formula 4.
Abstract:
A sphingosylphosphorylcholine(SPC) antagonist is provided to prevent and treat diseases related to the expression decrease of anti-bacterial peptide such as atopic dermatitis, and screen the SPC antagonist by analyzing the expression recover of gene or protein of the anti-bacterial peptide. The sphingosylphosphorylcholine(SPC) antagonist manufactures the medicine for restoring the expression of anti-bacterial peptide back to the normal level in mammal requiring the expression restoration of anti-bacterial peptide. The screening method of the sphingosylphosphorylcholine(SPC) antagonist comprises the steps of: treating the object with sphingosylphosphorylcholine or its derivative to inhibit expression of anti-bacterial peptide; and treating the object with the SPC antagonist candidate material, and analyzing the expression restoration level of the anti-bacterial peptide in the object.
Abstract:
A hexosamine derivative is provided to show excellent intra-abdominal fibrinous adhesion inhibitory activity, thereby being usefully used for preventing or treating post-operative adhesion. A pharmaceutical composition for preventing or treating post-operative adhesion such as intra-abdominal fibrinous adhesion comprises a hexosamine compound represented by a formula(1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the active ingredient is selected from the group consisting of galactosamine, D-(+)-glucosamine hydrochloride, and D-(+)-galactosamine hydrochloride.
Abstract:
본 발명은 생강, 건강, 오수유 및 초두구로 이루어진 군으로부터 선택된 하나 이상의 추출물을 유효성분으로 함유하는 조성물에 관한 것으로서, 구체적으로 본 발명의 추출물은 뛰어난 가려움증 억제 효과를 나타내어, 염증성 피부염, 아토피성 피부염 등으로부터 유발되는 가려움증의 억제 및 완화용 조성물로 유용하게 이용될 수 있다. 생강, 건강, 오수유, 초두구, 가려움증, 소양증, 피부 외용제